2014-01-30 15:10:20 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Renhe Pharmacy Co., Ltd. (650) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Renhe Pharmacy Co., Ltd. (650). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Renhe Pharmacy Co., Ltd. investor.
Report Summary: Renhe Pharmacy Co., Ltd. is a below average quality company with a positive outlook. Renhe Pharmacy Co., Ltd. has strong business growth and is run by efficient management. The trend in Renhe Pharmacy Co., Ltd. fair value exchange rate against its closest rated-competitor, Changzhou Qianhong Bio Pharma Co Ltd, has been stable over the past 2 weeks. When compared to its closest competitor, Renhe Pharmacy Co., Ltd. shows similar overvaluation and is equally likely to underperform the
The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Renhe Pharmacy Co., Ltd. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.